"Two serological tests were done: a point-of-care rapid test applied directly to fingerprick blood, and a chemiluminescent microparticle immunoassay that requires venepuncture for subsequent analysis in laboratory."

The point-of-care test was a lateral-flow immunochromatographic assay for qualitative differentiation between IgG and IgM against the receptor binding domain of SARS-CoV-2 spike (S) protein.

"The second test was a chemiluminescent microparticle immunoassay for qualitative detection of IgG against SARS-CoV-2 nucleoprotein."